Market Signal Briefing

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Skye class action, go to https://rosenlegal.com/submit-form/?case_id=48064 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements regarding Skye’s business, operations, and prospects. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (1) nimacimab was less effective than defendants had led investors to believe; (2) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Skye Bioscience class action, go to https://rosenlegal.com/submit-form/?case_id=48064 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Regeneron Pharmaceuticals, Inc. (REGN) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 5:15 PM EST

Company Participants

Leonard Schleifer - Co-Founder, President, CEO & Co-Chairman
George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman

Conference Call Participants

Christopher Schott - JPMorgan Chase & Co, Research Division

Presentation

Christopher Schott
JPMorgan Chase & Co, Research Division

Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Regeneron today. From the company, we have Regeneron's Co-Founders and Co-Chairs President and CEO, Len Schleifer; and President and CSO, George Yancopoulos. Between the core portfolio and an increasingly broad pipeline, I'm very much looking forward to the presentation today. So with that, over to Len, and we'll go to some Q&A after that.

Leonard Schleifer
Co-Founder, President, CEO & Co-Chairman

Thanks, Chris. It's great to be here. We're going to try and do maybe 20 minutes of presentation and then leave it to you for questions. It's great to be back in San Francisco for the 44th I guess JPMorgan Conference. .

We think it's a very interesting conference. It mainly got interesting 37 years ago when we started presenting. We have been in every room at the conference. And in every single room many times the most common phrase that we have heard, so it shows how consistent the place is, is promising data.

Okay. We -- that went over well. That's my team said, don't do it Len. Anyway, I'm Len Schleifer, CEO of Regeneron. I'm joined on stage by my longtime partner Regeneron, Dr. George Yancopoulos, Regeneron's Chief Scientific Officer and Co-Founder. During our presentation, we will be referring to slides, which may be found on our website.

This is one of my -- this one is one of my favorite slides. It contains our forward-looking statements. There's

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nutanix, Inc. (“Nutanix” or “the Company”) (NASDAQ: NTNX) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Nutanix reported its financial results for Q1 2026 on November 25, 2025. The Company’s revenue was near the bottom of its prior guidance. The Company blamed a "revenue shift from Q1 to future periods,” as well as factors including customer demand for flexible start dates. The Company lowered its full-year revenue projection. Based on this news, shares of Nutanix fell by 17.8% on the next day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Key Takeaways ZM shares were widely hailed during the COVID-era. Weak sales growth has been an issue. The stock now sports a Zacks Rank #1 (Strong Buy). A handful of stocks benefited massively during the pandemic. It was an interesting time to be an investor, to say the least, and those who targeted the stay-at-home stocks were rewarded handsomely with considerable gains.

One of those stocks includes Zoom Video Communications (ZM - Free Report) . The stock currently sports a Zacks Rank #1 (Strong Buy), reflective of bullish EPS revisions among analysts. Is it time for the stock to finally regain some attention?

Zoom Video Communications

Zoom Video Communications’ cloud-native unified communications platform combines video, audio, phone, screen sharing, and chat functionalities. It’s easy to understand why shares gained popularity during that period, as many were forced onto the platform for both personal and professional reasons.

Sales exploded during the pandemic before leveling off significantly over recent years, as shown below. The weak top-line performance has been a major thorn in the side, explaining the poor price action we’ve seen since the COVID era.

Image Source: Zacks Investment Research

EPS expectations for its current fiscal year reflect positivity, with the current $5.96 Zacks Consensus EPS estimate up nearly 13% over the last year. Revenue revisions have followed a similar positive path, with the $4.8 billion expected in its current fiscal year up by roughly 2% over the same timeframe.

Image Source: Zacks Investment Research

Bottom Line

While stocks such as Zoom Video Communications (ZM - Free Report) were widely hailed during the pandemic, the attention since has drastically reduced.  A return to office post-COVID and other similar developments stunted the company’s growth in a big way, with shares suffering as a result.

The stock has quietly consolidated since, with recent positive estimate revisions pushing the once-beloved stock into a Zacks Rank #1 (Strong Buy).

Investors are getting more excited about the online retail giant's artificial intelligence (AI) initiatives.

Shares of Alibaba Group (BABA +10.17%) leaped on Monday, following several positive developments for the Chinese commerce and cloud computing titan.

By the close of trading, Alibaba's stock price was up more than 10%.

Image source: Alibaba Group.

Alibaba is becoming a formidable force in the AI arena The South China Morning Post (which is owned by Alibaba) highlighted a report from AIBase showing that Alibaba's Qwen artificial intelligence (AI) models were downloaded more than 700 million times as of this month.

If the report is accurate, that would make Alibaba's models the most popular open-source AI models in the world today, surpassing those offered by OpenAI, Meta Platforms, and other leading AI developers.

Today's Change

(

10.17

%) $

15.35

Current Price

$

166.31

According to the report, "Tens of thousands of real-world applications around the globe have been built based on Qwen, marking a historic peak for [Chinese] open-source large models within the international developer community."

Qwen's success could help to fuel the growth of Alibaba's lucrative cloud computing business. Revenue in its cloud division surged 34% year over year to $5.6 billion in the quarter ended Sept. 30.

Regulatory pressure may be easing Alibaba's share price also likely benefited from reports that Chinese regulators were moving to curb a price war raging within the country's food-delivery industry. The new regulatory stance could boost Alibaba's profit margins by increasing compliance costs, according to Bloomberg.

Higher compliance costs favor bigger enterprises like Alibaba, which can spread those costs over their larger revenue bases. The e-commerce colossus's smaller rivals would find it more difficult to afford those costs, thereby reducing competition.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Alibaba Group. The Motley Fool has a disclosure policy.

Deutsche Bank Aktiengesellschaft now trades above book value, signaling a shift from recovery to maintenance rather than a new growth phase. Recent Tier 2 bond issuance reflects market confidence in DB's long-term viability and enhances downside protection for equity holders. Future equity upside relies on DB delivering consistent returns, tight cost control, and predictable capital distributions, as mechanical buyback benefits fade at book value.

Kodiak Sciences Inc. (KOD) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 4:30 PM EST

Company Participants

Victor Perlroth - Co-Founder, Chairman, CEO & President

Conference Call Participants

Anupam Rama - JPMorgan Chase & Co, Research Division

Presentation

Anupam Rama
JPMorgan Chase & Co, Research Division

All right. Welcome, everyone, to the 44th Annual J.P. Morgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at J.P. Morgan. I'm joined by my squad, Priyanka Grover, Joyce Zhou and Rati Pinhe. Our next presenting company is Kodiak. And presenting on behalf of the company, we have CEO, Victor Perlroth. Victor?

Victor Perlroth
Co-Founder, Chairman, CEO & President

Thank you, Anupam. Well, each year at the J.P. Morgan, the metronome of the different years, it's great to be here. Thank you. But I also remember the R&D Day that Kodiak had in July of last year. I think at that time, I said I couldn't be more excited and enthusiastic about what we had in front of us. And now looking 6 months later, we've made tremendous progress on the plans that we articulated at that time. I think what I also like to say is many good things that could have happened did happen and many bad things that could have happened didn't. I think as I look and as we look at Kodiak to 2026 and into 2027, it's a tremendously exciting time for us. I continue to be very pleased with all of the progress and everything that I see at the company.

We're going to, as usual, run through quite a lot of content. There is a lot under the hood at Kodiak, and we'll try to do that in a time-efficient manner. First, remember our forward-looking statements. Please read carefully all of the SEC documentations, including the

, /PRNewswire/ -- Vistra Corp. (NYSE: VST) (the "Company" or "Vistra") announced today the pricing of a private offering (the "Offering") of $2.25 billion aggregate principal amount of senior secured notes, consisting of $1.0 billion aggregate principal amount of senior secured notes due 2031 at a price to the public of 99.954% of their face value (the "2031 Notes") and $1.250 billion aggregate principal amount of senior secured notes due 2036 at a price to the public of 99.745% of their face value (the "2036 Notes" and, together with the 2031 Notes, the "Notes")  to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to certain non-U.S. persons in accordance with Regulation S under the Securities Act. The Notes will be senior, secured obligations of Vistra Operations Company LLC, a Delaware limited liability company and an indirect wholly owned subsidiary of the Company (the "Issuer"). The 2031 Secured Notes will bear interest at the rate of 4.700% per annum and the 2036 Secured Notes will bear interest at the rate of 5.350% per annum. The Notes will be fully and unconditionally guaranteed by certain of the Issuer's current and future subsidiaries that also guarantee the Issuer's Credit Agreement, dated as of October 3, 2016 (as amended, the "Credit Agreement"), by and among the Issuer, as borrower, Vistra Intermediate Company LLC, the guarantors party thereto, Citibank, N.A., as administrative and collateral agent, various lenders and letter of credit issuers party thereto, and the other parties named therein. The Notes will be secured by a first-priority security interest in the same collateral that is pledged for the benefit of the lenders under the Credit Agreement and certain other agreements, which consists of a substantial portion of the property, assets and rights owned by the Issuer and the subsidiary guarantors as well as the equity interest of the Issuer. The collateral securing the Notes will be released if the Issuer's senior, unsecured long-term debt securities obtain an investment grade rating from two out of the three rating agencies, subject to reversion if such rating agencies withdraw the investment grade rating of the Issuer's senior, unsecured long-term debt securities or downgrade such rating below investment grade.

The Company intends to use the proceeds from the Offering (i) to fund a portion of the consideration for the previously announced acquisition by the Company of Cogentrix Energy (the "Cogentrix Transaction"), (ii) for general corporate purposes, including to repay existing indebtedness and/or (iii) to pay fees and expenses related to the Offering.

The Offering is expected to close on January 22, 2026, subject to customary closing conditions.

The Notes will not be registered under the Securities Act or the securities laws of any state or other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities described above, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Vistra
Vistra (NYSE: VST) is a leading Fortune 500 integrated retail electricity and power generation company based in Irving, Texas, that provides essential resources to customers, businesses, and communities from California to Maine. Vistra is a leader in transforming the energy landscape, with an unyielding focus on reliability, affordability, and sustainability. The company safely operates a reliable, efficient power generation fleet of natural gas, nuclear, coal, solar, and battery energy storage facilities while taking an innovative, customer-centric approach to its retail business. Learn more at vistracorp.com.

Cautionary Note Regarding Forward-Looking Statements
The information presented herein includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are based on current expectations, estimates and projections about the industry and markets in which Vistra operates and beliefs of and assumptions made by Vistra's management, involve risks and uncertainties, which are difficult to predict and are not guarantees of future performance, that could significantly affect the financial results of Vistra. All statements, other than statements of historical facts, that are presented herein, or in response to questions or otherwise, that address activities, events or developments that may occur in the future, including such matters as activities related to our financial or operational projections, financial condition and cash flows, projected synergy, net debt targets, capital allocation, capital expenditures, liquidity, projected Adjusted EBITDA to free cash flow conversion rate, dividend policy, business strategy, competitive strengths, goals, future acquisitions or dispositions, development or operation of power generation assets, market and industry developments and the growth of our businesses and operations, including potential transactions with large load facilities at our nuclear and natural gas plants (often, but not always, through the use of words or phrases, or the negative variations of those words or other comparable words of a future or forward-looking nature, including, but not limited to: "intends," "plans," "will likely," "unlikely," "believe," "confident", "expect," "seek," "anticipate," "estimate," "continue," "will," "shall," "should," "could," "may," "might," "predict," "project," "forecast," "target," "potential," "goal," "objective," "guidance" and "outlook"), are forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. Although Vistra believes that in making any such forward-looking statement, Vistra's expectations are based on reasonable assumptions, any such forward-looking statement involves uncertainties and risks that could cause results to differ materially from those projected in or implied by any such forward-looking statement, including, but not limited to: (i) adverse changes in general economic or market conditions (including changes in interest rates) or changes in political conditions or federal or state laws and regulations; (ii) the ability of Vistra to execute upon its contemplated strategic, capital allocation, performance, and cost-saving initiatives, including the closing of the Cogentrix Transaction, and to successfully integrate acquired businesses; (iii) actions by credit ratings agencies; (iv) the severity, magnitude and duration of extreme weather events, contingencies and uncertainties relating thereto, most of which are difficult to predict and many of which are beyond our control, and the resulting effects on our results of operations, financial condition and cash flows; and (v) those additional risks and factors discussed in reports filed with the Securities and Exchange Commission by Vistra from time to time, including the uncertainties and risks discussed in the sections entitled "Risk Factors" and "Forward-Looking Statements" in Vistra's annual report on Form 10-K for the year ended December 31, 2024 and any subsequently filed quarterly reports on Form 10-Q.

Any forward-looking statement speaks only at the date on which it is made, and except as may be required by law, Vistra will not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date on which it is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible to predict all of them; nor can Vistra assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement.

SOURCE Vistra Corp

By PYMNTS  |  January 12, 2026

 | 

Wayfair said Monday (Jan. 12) that it participated in the development of Google’s Universal Commerce Protocol (UCP) for agentic commerce and will soon enable shoppers to check out directly from Wayfair without leaving Google during their research.

The new checkout experience will be enabled by UCP on eligible Google product listings in AI Mode in Search and the Gemini app, the online seller of furniture and home goods said in a Monday (Jan. 12) press release.

In this experience, Wayfair will be the merchant of record, ensuring consistent pricing, fulfillment and customer support, the release said.

Wayfair is working with other retailers on UCP and other standards to help ensure that AI-driven shopping experiences connect customers with trusted merchants, Wayfair Chief Technology Officer Fiona Tan said in the release.

“Wayfair is investing in AI-powered discovery wherever our customers are — whether that is on our own app or across external AI platforms,” Tan said. “The Universal Commerce Protocol serves as the common language for this new ecosystem. It allows agents to bridge the gap between discovery and checkout, while ensuring we remain the merchant of record to guarantee the quality of the service.”

In a Monday blog post on this topic, Wayfair said: “Agentic commerce is still in its early stages, but it points to a more intuitive, conversational and personalized future for shopping. By helping define open standards now, Wayfair is investing in experiences that make it easier for customers to move from inspiration to confident purchase.”

Advertisement: Scroll to Continue

PYMNTS reported in August that Wayfair was leaning into AI with consumer-facing AI initiatives like the Decorify and Muse platforms, which allows customers to visualize and personalize home design, and the new Discover tab in the company’s app that showcases AI-curated content.

In addition, Wayfair CEO Niraj Shah said at the time during an earnings call, the company is working to optimize interactions so that AI platforms and understand and recommend Wayfair.

Google debuted UCP Monday, saying this agentic commerce standard was developed in collaboration with Wayfair, Shopify, Etsy, Target and Walmart.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds all former stockholders of Smartsheet Inc. (NYSE: SMAR) in connection with the January 2025 sale (the "Merger" or "Buyout") of Smartsheet to affiliates of investment funds managed by affiliates of Blackstone Inc. (collectively "Blackstone"), investment funds managed by Vista Equity Partners Management, LLC ("Vista Equity Partners" or "Vista"), and Platinum Falcon B 2018 RSC Limited, an indirect wholly owned subsidiary of the Abu Dhabi Investment Authority, which participated as an indirect minority investor in Smartsheet ("Platinum Falcon," and together with Blackstone and Vista, the "Consortium"), of the important February 24, 2026 lead plaintiff deadline.

So What: If you are a former Smartsheet stockholder, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Smartsheet class action, go to https://rosenlegal.com/submit-form/?case_id=49166 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 24, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: The complaint alleges that in connection with Smartsheet's solicitation of stockholder approval of the Buyout, defendants issued and filed with the SEC a false and misleading Schedule 14A Proxy statement, as amended (the "Proxy"). Defendants used the Proxy to intentionally mischaracterize Smartsheet's financial success and performance during and in the context of Smartsheet's sales process. Specifically, defendants deliberately cast Smartsheet's quarterly earnings in a negative light in the Proxy, and emphasized a financial metric that it apparently made up just for the purposes of soliciting approval for the Buyout. Additionally, it was alleged that defendant Mark P. Mader failed to use reasonable care in the fulfillment of his disclosure duties.

To join the Smartsheet class action, go to https://rosenlegal.com/submit-form/?case_id=49166 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

By PYMNTS  |  January 12, 2026

 | 

Capital One will reportedly pay $425 million and pay higher interest rates on certain accounts to settle a class action lawsuit alleging that depositors were cheated out of high interest rates.

The bank’s addition of higher interest rates for depositors with 360 Savings accounts gained a federal judge’s preliminary approval of the revised settlement after he had rejected an earlier one, Reuters reported Monday (Jan. 12).

The higher interest rates will deliver about $530 million to the depositors, in addition to the $425 million payment that was included in the earlier proposed settlement that was rejected by the judge, according to the report.

Capital One did not immediately reply to PYMNTS’ request for comment.

In the class action lawsuit, customers accused the bank of falsely promising high interest rates on its 360 Savings accounts while offering much better rates to new customers on its 360 Performance Savings accounts.

It was reported in May that Capital One would pay $425 million to settle the lawsuit without admitting any wrongdoing. That figure included $300 million to cover interest the 360 Savings depositors could have gotten with 360 Performance Savings accounts, as well as $125 million in interest to depositors who still have 360 Savings accounts.

Advertisement: Scroll to Continue

In September, 18 state attorneys general filed an amicus brief asking the court to reject the proposed class action settlement in the case, which was separate from a lawsuit brought by the states. They argued that the settlement would shortchange Capital One customers.

A federal judge rejected that proposed settlement in November, saying that the payout was too small and that the strength of the plaintiffs’ claims justified “significantly greater relief.” He said the deal seemed to give 360 Savings depositors less than 10% of their damages and left them with the low-yielding accounts while 360 Performance Savings customers earned four to eight times more.

The judge ordered both sides to return to the negotiating table to address his concerns.

New York Attorney General Letitia James, who led the coalition of attorneys general opposing the earlier proposed settlement, said in a Monday press release that she applauded the new settlement because it delivers justice and ensures Capital One customers will get the higher interest rates they were originally promised.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of QSR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Mike Doustdar, Novo Nordisk president and CEO, joins 'Mad Money' host Jim Cramer to talk the success of GLP-1, pricing for weight-loss pills and more.

Biogen Inc. (BIIB) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 4:30 PM EST

Company Participants

Christopher Viehbacher - President, CEO & Director

Conference Call Participants

Christopher Schott - JPMorgan Chase & Co, Research Division

Presentation

Christopher Schott
JPMorgan Chase & Co, Research Division

Good afternoon, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be introducing Biogen today. We have the company's CEO, Chris Viebacher, who's going to talk about the progress the company has made across its portfolio. So Chris, happy New Year. Looking forward to the presentation, and we'll jump to a Q&A session once Chris is done.

Christopher Viehbacher
President, CEO & Director

Thank you, Chris. Happy New Year, everybody. I think I should be well managed here. I've got my current Head of IR and my prior Head of IR from Sanofi here with me to make sure I don't screw up. All right. So exciting year at Biogen. We've been on a long journey. The -- obviously, the MS portfolio has been declining. I think the first year I was here as CEO of Biogen, we talked about the melting iceberg. And this is a period where every pharma company gets at one point, where the growth drivers of your business are arriving at the end of their intellectual property lives and the new company has to emerge. And so the playbook for that is really what we've been doing here. The first one, we need to actually manage our cost base.

And it's not just about cutting costs. I mean we did achieve the $1 billion in gross cost savings, $800 million in net. But it was really around redesigning the organization. Biogen had been historically focused on multiple sclerosis, and yet we were launching new drugs in Alzheimer's and postpartum depression and not to

Mike Doustdar, Novo Nordisk president and CEO, joins 'Mad Money' host Jim Cramer to talk the success of GLP-1, pricing for weight-loss pills and more.

Oxford Nanopore Technologies plc (ONTTF) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 5:15 PM EST

Company Participants

Gordon Sanghera
Nicholas Keher - CFO & Director

Conference Call Participants

Zain Ebrahim - JPMorgan Chase & Co, Research Division

Presentation

Zain Ebrahim
JPMorgan Chase & Co, Research Division

Good afternoon, everyone, and welcome to the 2026 JPMorgan Healthcare Conference. My name is Zain Ebrahim. I'm a European pharma and life sciences analyst here at JPMorgan. It's my great pleasure to welcome the Oxford Nanopore CEO, Gordon Sanghera; as well as the CFO, Nick Keher, who will join Dr. Sanghera for the Q&A. So as a reminder, we'll follow the usual structure, 20 minutes presentation followed by 20 minutes Q&A, where you'll be able to ask questions either in the audience or through the web link. And with that, I'll hand over to Gordon. Thank you for being here.

Gordon Sanghera

Thanks, Zain. Afternoon, everybody. Okay. This has been a 20-year journey for me. We set the company up, spun out of Oxford, I was employee #1, often referred to as patient #1, still here, still going. I am coming to the end of my tenure at the end of this quarter. But our goal 20 years ago was to develop a single molecule electronic sensing platform. The company's vision was to enable the analysis of anything by anyone anywhere. So work in progress. We've done some amazing things from having sequencers in space to the marina trench and Antarctic, not Greenland, I don't think, but maybe we shouldn't talk about Greenland today.

Anyway, in that 20 years, we have developed DNA/RNA sequencing. And we are now extending the platform to proteomics as well. I'll talk a little bit about that later. It has the potential as well to measure metabolites and also volatile organic

Twist Bioscience Corporation (TWST) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 5:15 PM EST

Company Participants

Emily Leproust - Co-Founder, Board Chair & CEO
Adam Laponis - Chief Financial Officer

Conference Call Participants

Ryan Rice

Presentation

Ryan Rice

Good afternoon, everyone. My name is Ryan Rice, and I'm an associate with the JPMorgan Healthcare Investment Banking team. Welcome to the session for Twist Bioscience. Presenting today, we have the Twist Bioscience CEO and Co-Founder, Dr. Emily Leproust; joined by the CFO, Adam Laponis. The presentation today will be about 20 minutes, followed by roughly 20 minutes of Q&A. So we please just ask you to hold your questions until the end. I'll go ahead and turn it over to Emily to get started. Thank you.

Emily Leproust
Co-Founder, Board Chair & CEO

Thank you very much for the invitation and the introduction. I'll start by saying that I'll be making some forward-looking statements today. So at Twist, we are an emerging leader in life science tools, we are global, and we outperform in the multibillion-dollar markets that we serve.

And the key technology for us is a semiconductor approach to DNA synthesis. Our products are actually very diverse. We serve many applications. One of them is DNA synthesis and protein solutions that you may know formerly as SynBio and Biopharma. The other is NGS application formerly NGS. And the key applications we serve are the therapeutic drug discovery, diagnostics, the chemical production -- the production of chemicals through yeast, algae and E coli in a way that's more sustainable and enabling our customers to make sure that our food security is there through the engineering of traits in plants and animals.

We serve the top of the top institutions in multiple markets. We have more than almost 4,000

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ZOMD:CA over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Bath & Body Works, Inc. (NYSE: BBWI) securities between June 4, 2024 and November 19, 2025. Bath & Body Works is a specialty retailer of home fragrance and body care products.

Robbins LLP is Investigating Allegations that Bath & Body Works, Inc. (BBWI) Misled Investors Regarding its Business Strategy

Share For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Bath & Body Works, Inc. (BBWI) Misled Investors Regarding its Business Strategy

According to the complaint, defendants failed to disclose to investors: (1) the Company's strategy of pursuing "adjacencies, collaborations and promotions" was not growing the customer base and/or delivering the level of growth in net sales touted; (2) as the Company's strategy of "adjacencies, collaborations and promotions" faltered, the Company relied on brand collaborations "to carry quarters" and obfuscate otherwise weak underlying financial results; and (3) as a result, the Company was unlikely to meet its own previously issued financial guidance.

Plaintiff alleges that on November 20, 2025, Bath & Body Works released disappointing third quarter 2025 financial results, including that revenue declined 1% year over year, missed guidance of 1-3% growth for the quarter, and a decline in net income by 26% to $77 million. The Company slashed full-year guidance for net sales and cut expected earnings per diluted share from $3.28 to $3.53 to "at least $2.83."

In an investor presentation published the same day, the Company announced a new business strategy and admitted its strategy of "adjacencies, collaborations and promotions" had "not grown our total customer base." The Company also offered a "diagnosis" of its underperformance, including that the focus on adjacencies had "reduced focus on investing in our core categories;" that collaborations "have been used to carry quarters;" and that the Company had become "overly reliant on deeper and more frequent promotions to drive growth. " The Company announced would exit certain adjacencies and instead focus on core categories.

On this news, Bath & Body Works' stock price fell $5.22, or 24.8%, to close at $15.82 per share on November 20, 2025

What Now: You may be eligible to participate in the class action against Bath & Body Works, Inc. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Bath & Body Works, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

A boom-and-bust region is feeling the pinch from cheap oil, even as low prices help at the pump.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock, you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

All amounts in U.S. dollars

BROOKFIELD, News, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Brookfield Renewable Corporation (NYSE: BEPC; TSX: BEPC) (“BEPC”) and Brookfield Renewable Partners L.P. (NYSE: BEP; TSX: BEP.UN) (the “Partnership” and together with BEPC, “Brookfield Renewable”) today announced that they have made the necessary Canadian and U.S. securities filings to enable an “at the market” equity issuance program (the “ATM Program”) of class A exchangeable subordinate voting shares of BEPC (the “BEPC Shares”). Under the ATM Program, BEPC may, at its discretion, offer and sell up to $400 million (or the Canadian dollar equivalent) of BEPC Shares directly from treasury.

Brookfield Renewable intends to use the net proceeds from the ATM Program, if any, to facilitate repurchases by the Partnership of its non-voting limited partnership units (each, an “LP Unit”) under its normal course issuer bid (“NCIB”) program (subject to compliance with applicable securities laws) and for general corporate purposes.

Overall, the ATM Program, if exercised, is expected to be non-dilutive to Brookfield Renewable, as the combined number of LP Units and BEPC Shares outstanding is intended to remain generally unchanged, though there may be temporary fluctuations over the course of the issuances of BEPC Shares and corresponding repurchases of LP Units.

ATM Program Details

Under the ATM Program, BEPC Shares may be sold to the public from time to time at prevailing market prices through the Toronto Stock Exchange, the New York Stock Exchange or any other marketplace in Canada or the United States where BEPC Shares may be traded. As a result, sale prices of the BEPC Shares sold under the ATM Program, if any, may vary among purchasers and throughout the distribution period. The ATM Program will provide BEPC with flexibility to issue BEPC Shares directly into the market at times when conditions are determined to be favorable.

Each BEPC Share will be exchangeable at the option of the holder for one LP Unit (subject to adjustment to reflect certain capital events) or its cash equivalent (the form of payment to be determined at the election of BEPC).

The BEPC Shares will be offered pursuant to an equity distribution agreement dated January 12, 2026 (the “Distribution Agreement”) entered among the Partnership, BEPC and BMO Nesbitt Burns Inc. and TD Securities Inc. (together, the “Canadian Agents”), and BMO Capital Markets Corp. and TD Securities (USA) LLC (together, the “U.S. Agents” and, together with the Canadian Agents, the “Agents”, each an “Agent”). Sales may be made through “at the market distributions” as defined in National Instrument 44-102 – Shelf Distributions and in sales deemed to be an “at the market offering” as defined in Rule 415 promulgated under the U.S. Securities Act of 1933, as amended, and as otherwise permitted by applicable laws. The ATM Program will terminate upon the earlier of (i) the sale of all of the BEPC Shares subject to the Distribution Agreement, (ii) termination of the Distribution Agreement by BEPC or by the Agents as provided therein, or (iii) on February 24, 2027, in each case in accordance with the terms of the Distribution Agreement. 

The ATM Program is being undertaken in Canada pursuant to a Canadian prospectus supplement dated January 12, 2026 (the “Canadian Prospectus Supplement”) to the Partnership and BEPC’s Canadian short form base shelf prospectus dated January 23, 2025 (together with the Canadian Prospectus Supplement, the “Canadian Prospectus”), which has been filed in each of the provinces and territories of Canada, and in the United States pursuant to a U.S. prospectus supplement dated January 12, 2026 (the “U.S. Prospectus Supplement”) to BEPC’s and the Partnership’s U.S. base prospectus dated April 2, 2025 (together with the U.S. Prospectus Supplement, the “U.S. Prospectus”) that supplements the preliminary base prospectus included in their joint U.S. registration statement on Form F-3, filed with the U.S. Securities and Exchange Commission on April 5, 2024 (as amended on March 6, 2025, and declared effective on April 2, 2025). Before making an investment, potential investors should read the Canadian Prospectus or the U.S. Prospectus, as applicable, and other public filings by Brookfield Renewable for more information about Brookfield Renewable and the ATM Program. Copies of these documents, as well as the Distribution Agreement, are available on SEDAR+ at www.sedarplus.ca or on EDGAR at www.sec.gov. The Agents participating in the ATM Program will arrange to send you the Canadian Prospectus or the U.S. Prospectus and the Distribution Agreement, as applicable, upon request by contacting, in the case of the Canadian Prospectus or the Distribution Agreement, BMO Nesbitt Burns Inc., 9195 Torbram Road, Brampton, Ontario, L6S 6H2, attention: Brampton Distribution Centre C/O The Data Group of Companies, phone: 1-905-791-3151 Ext 4312, email: [email protected]  or TD Securities Inc., 1625 Tech Avenue, Mississauga ON L4W 5P5, attention: Symcor, NPM, phone: (289) 360-2009, email: [email protected], or, in the case of the U.S. Prospectus or the Distribution Agreement, BMO Capital Markets Corp., 151 W 42nd St, 32nd floor, New York, NY 10036, attention: Equity Syndicate Department, phone: 1-800-414-3627, email: [email protected] or TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, email: [email protected].

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Brookfield Renewable, nor will there be any sale of the securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Brookfield Renewable

Brookfield Renewable operates one of the world’s largest publicly traded platforms for renewable power and sustainable solutions. Our renewable power portfolio consists of hydroelectric, wind, utility-scale solar, distributed solar and storage facilities and our sustainable solutions assets include our investment in a leading global nuclear services business and a portfolio of investments in carbon capture and storage capacity, agricultural renewable natural gas, materials recycling and eFuels manufacturing capacity, among others.

Investors can access the portfolio either through Brookfield Renewable Partners L.P. (NYSE: BEP; TSX: BEP.UN), a Bermuda-based limited partnership, or Brookfield Renewable Corporation (NYSE, TSX: BEPC), a Canadian corporation.

Brookfield Renewable is the flagship listed renewable power and transition company of Brookfield Asset Management, a leading global alternative asset manager headquartered in New York, with over $1 trillion of assets under management.

For more information, please contact:

Cautionary Statement Regarding Forward-looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities laws. The words “may”, “intends”, “expected”, “will” or derivations thereof and other expressions which are predictions of or indicate future events, trends or prospects, and which do not relate to historical matters, identify forward-looking statements. Forward-looking statements in this news release include statements regarding the potential distribution of BEPC Shares pursuant to the ATM Program, the aggregate value of BEPC Shares that may be issued pursuant to the ATM Program, the expectation that the ATM Program is expected to be non-dilutive and that the aggregate number of LP Units and BEPC Shares is intended to be generally unchanged over the course of the ATM Program, the expected use of net proceeds, if any, from the ATM Program and the potential repurchases by the Partnership of its LP Units under its NCIB program. Although Brookfield Renewable believes that these forward-looking statements and information are based upon reasonable assumptions and expectations, the reader should not place undue reliance on them, or any other forward-looking statements or information in this news release. The future performance and prospects of Brookfield Renewable are subject to a number of known and unknown risks and uncertainties. Factors that could cause actual results of Brookfield Renewable to differ materially from those contemplated or implied by the statements in this news release are described in the documents filed by Brookfield Renewable with the securities regulators in Canada and the United States, including under “Risk Factors” in the Canadian Prospectus and the U.S. Prospectus, each of BEPC and the Partnership’s most recent Annual Report on Form 20-F and the other documents incorporated by reference in the Canadian Prospectus and the U.S. Prospectus.

Except as required by law, Brookfield Renewable does not undertake any obligation to publicly update or revise any forward-looking statements or information, whether written or oral, whether as a result of new information, future events or otherwise.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of KOF, FMX, PEP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

January 12, 2026 18:56 ET  | Source: JBS USA Food Company

Amstelveen, Netherlands, Jan. 12, 2026 (GLOBE NEWSWIRE) -- JBS N.V. (the “Company,” “JBS,” “we” or “us”) (NYSE: JBS; B3: JBSS32), together with JBS USA Foods Group Holdings, Inc. and JBS USA Food Company Holdings (collectively, the “Co-Issuers”), announced today the expiration and results of its previously announced offers to exchange (the “Exchange Offers”) any and all of the outstanding Old Notes (as defined below) for an equal principal amount of new notes (the “New Notes”) in a transaction registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”).

The Exchange Offers expired at 5:00 p.m., New York City time, on January 12, 2026 (the “Expiration Date”). As of the Expiration Date, the aggregate principal amount of each series of the Old Notes set forth in the table below had been validly tendered and not validly withdrawn. The Co-Issuers have accepted for exchange all such tendered Old Notes in the Exchange Offers.

Title of Series / CUSIP/ISIN Number of Old Notes (the “Old Notes”)
 Aggregate Principal Amount Outstanding
  Old Notes Tendered as of
Expiration Date    Principal Amount  Percentage 5.950% Senior Notes due 2035            (472140 AA0 and L56900 AA8/
US472140AA00 and USL56900AA86) US$1,000,000,000  US$992,404,000   99.24%6.375% Senior Notes due 2055            472140 AC6 and L56900 AB6/
US472140AC65and USL56900AB69 US$750,000,000  US$749,800,000   99.97%5.500% Senior Notes due 2036            (472140AE2 and L56900AC4/
US472140AE22 and USL56900AC43) US$1,250,000,000  US$1,245,607,000   99.65%6.250% Senior Notes due 2056            (472140 AG7 and L56900 AD2/
US472140AG79 and USL56900AD26) US$1,250,000,000  US$1,247,627,000   99.81%6.375% Senior Notes due 2066            (472140 AJ1 and L56900AE0/
US472140AJ19 and USL56900AE09) US$1,000,000,000  US$994,858,000   99.49%              Upon the settlement of the Exchange Offers, holders of Old Notes who validly tendered and did not validly withdraw such Old Notes prior to the Expiration Date will receive an equivalent principal amount of New Notes of the applicable series. JBS expects that such settlement will occur on or about January 14, 2026.

The terms of the New Notes are identical in all material respects to the terms of the corresponding series of Old Notes, except that the New Notes have been registered under the Securities Act, will not be subject to transfer restrictions or registration rights, and the New Notes will bear different CUSIP numbers from the Old Notes of the corresponding series. None of the Co-Issuers will receive proceeds from the Exchange Offers.   The Co-Issuer will issue the New Notes under the same indentures that govern the applicable series of Old Notes. The Exchange Offers do not represent a new financing transaction.

The Exchange Offers have been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), pursuant to an effective registration statement on Form F-4 filed with the Securities and Exchange Commission. The Exchange Offers were made pursuant to the terms and subject to the conditions set forth in a prospectus dated December 11, 2025, which has been filed with the Securities and Exchange Commission and forms a part of the Registration Statement.

THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT AN OFFER TO EXCHANGE, OR A SOLICITATION OF AN OFFER TO EXCHANGE, ANY SECURITIES DESCRIBED HEREIN.

Important Notice Regarding Forward-Looking Statements:

This press release contains certain forward-looking statements. Statements that are not historical facts, including statements about our perspectives and expectations, are forward-looking statements. The words “expect,” “believe,” “estimate,” “intend,” “plan” and similar expressions, when related to JBS N.V. and its subsidiaries, indicate forward-looking statements. These statements reflect the current view of management and are subject to various risks and uncertainties. Actual results could differ materially from those expressed in, or implied or projected by these forward-looking statements as a result of these risks and uncertainties, many of which are difficult to predict and beyond JBS N.V.’s control. JBS N.V.’s forward-looking statements in this press release speak only as of the date hereof, and JBS N.V. undertakes no obligation to update any such statement after the date of this press release, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

D.F. King & Co., Inc., as Exchange Agent
28 Liberty Street, 53rd Floor
New York, NY 10005
Attn: Michael Horthman
Email: [email protected]
Toll Free: (877) 283-0318
Banks and Brokers Call: (646) 759-4548
By Facsimile Transmission (eligible institutions only): (212) 709-3328
For Information or Confirmation by Telephone: (212) 232-3233

By Reuters

January 13, 202612:03 AM UTCUpdated ago

Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

CompaniesJan 12 (Reuters) - Abbvie (ABBV.N), opens new tab reached a three-year agreement with U.S. President Donald Trump's administration to provide low prices in Medicaid through TrumpRx, and pledged $100 billion over the next decade for research and development in the U.S., the company said on Monday.

Sign up here.

Reporting by Ruchika Khanna in Bengaluru; Editing by Chris Reese

Our Standards: The Thomson Reuters Trust Principles., opens new tab